Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Inhibikase Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 22 | 24 | +2 |
| Shares | 3.35M | 3.06M | −292.2K (−8.7%) |
| Value | $2.49M | $2.78M | +$292.1K (+11.7%) |
New holders (5)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 24,114 | $22.0K | 0.00% |
| CCG Wealth Management, LLC | 20,000 | $18.0K | 0.01% |
| Millennium Management LLC | 15,934 | $14.0K | 0.00% |
| StoneX Group Inc. | 13,313 | $12.1K | 0.00% |
| UBS Group AG | 7,499 | $7.00K | 0.00% |
Sold out (3)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Antara Capital LP | 403,000 | $299.0K |
| Shay Capital LLC | 10,708 | $8.00K |
| Citigroup Inc | 500 | $0 |